📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-30 11:15
0 analysed today
FollowTelegram
0
Today
151,853
All-time analysed
43,533
Positive
6,742
Negative
92,741
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
4 announcements match the current filters (relevance ≥ 5).
Mahamaya Lifesciences Re-designates Prashant Krishnamurthy as MD; Elevates Founder to Chairman
Mahamaya Lifesciences announced that its shareholders approved significant leadership changes at the meeting held on September 29, 2026. Founder Mr. Krishnamurthy Ganesan has been re-designated from Managing Director to Chairman effective November 01, 2026. Concurrently, Executive Director Mr. Prashant Krishnamurthy has been elevated to Managing Director effective November 01, 2026, marking a planned generational succession. Additionally, the company regularized Dr. Bhagirath Choudhary as Independent Director for a 3-year term from August 25, 2026, and re-appointed two Independent Directors for second 3-year terms starting December 11, 2026.
Confidence: HIGH
What changedFormal transition of executive leadership from the founder to the next-generation promoter, alongside independent board reappointment approvals.
Why it mattersEnsures governance continuity and operational succession for a company generating Rs 329.0 Cr in FY26 revenue.
Effective date of MD transition: November 01, 2026Independent Director term length: 3 consecutive yearsFY26 Revenue Context: Rs 329.0 Cr
📅 Short termNeutral market impact expected as the leadership shift represents an internal succession rather than an abrupt disruption.
📈 Long termSets the strategic direction under younger leadership while retaining founder guidance at the board level.
⚠ Risk flags
- Promoter family succession (Krishnamurthy Ganesan is the father of incoming MD Prashant Krishnamurthy)
Key Highlights
Prashant Krishnamurthy elevated to Managing Director effective November 01, 2026
Founder Krishnamurthy Ganesan transitioned from MD to Chairman effective November 01, 2026
Dr. Bhagirath Choudhary appointed Independent Director for a 3-year term starting August 25, 2026
Dr. Gopal Krishna Raju and Dr. Charudatta Digambar Mayee re-appointed as Independent Directors for 3-year terms effective December 11, 2026
👀 What to Watch
Track the strategic priorities and operational changes under the new Managing Director in upcoming quarterly earnings calls and annual reports.
Mahamaya Lifesciences Announces Leadership Succession: New MD & CFO Appointed
Mahamaya Lifesciences announced a planned leadership succession approved at its Board meeting on August 25, 2026. Prashant Krishnamurthy will step down as CFO on October 31, 2026, and take over as Managing Director effective November 01, 2026, while current MD Krishnamurthy Ganesan transitions to Executive Chairman. Amarendra Mohapatra has been elevated to the position of Chief Financial Officer effective November 01, 2026. Additionally, the Board appointed Bhagirath Choudhary as Additional Independent Director for a 3-year term and scheduled the 24th AGM for September 29, 2026.
Confidence: HIGH
What changedThe company executed a planned succession, transitioning the MD to Executive Chairman, promoting the CFO to MD, and naming a new CFO.
Why it mattersEnsures structured leadership continuity and governance realignment without sudden disruption to ongoing operations in the agrochemical business.
AGM Date: September 29, 2026Leadership Transition Effective Date: November 01, 2026Independent Director Term: 3 consecutive years
📅 Short termShareholders will vote on board appointments and remuneration changes at the AGM on September 29, 2026; operational continuity is expected.
📈 Long termBrings in next-generation executive leadership alongside a dedicated finance head to drive corporate strategy and growth.
Key Highlights
Prashant Krishnamurthy re-designated from Executive Director & CFO to Managing Director effective November 01, 2026
Current MD Krishnamurthy Ganesan transitions to Chairman and Executive Non-Independent Director from November 01, 2026
Amarendra Mohapatra appointed as Chief Financial Officer and KMP effective November 01, 2026
Bhagirath Choudhary appointed as Additional Independent Director for a 3-year term effective August 25, 2026
24th Annual General Meeting (AGM) scheduled for September 29, 2026
👀 What to Watch
Track shareholder approval for the director appointments and remuneration revisions at the 24th AGM on September 29, 2026.
Mahamaya Lifesciences Announces Key Leadership Changes; Elevates Prashant Krishnamurthy to MD
Mahamaya Lifesciences Limited has announced a leadership transition approved by its Board on August 25, 2026. Mr. Prashant Krishnamurthy will step down as CFO on October 31, 2026, and assume the role of Managing Director effective November 01, 2026, while current MD Mr. Krishnamurthy Ganesan transitions to Chairman and Executive Director. Mr. Amarendra Mohapatra has been elevated to Chief Financial Officer effective November 01, 2026, and Mr. Kush Mishra was appointed Company Secretary effective August 25, 2026.
Confidence: HIGH
What changedPromoter leadership transition where the current CFO becomes MD, the MD becomes Executive Chairman, and a new CFO and Company Secretary are appointed.
Why it mattersRepresents an internal management succession plan separating the MD and CFO responsibilities while maintaining promoter continuity at the board level.
MD Re-designation Effective Date: November 01, 2026New CFO Effective Date: November 01, 2026AGM Date: September 29, 2026FY26 Revenue: Rs 329.0 cr
📅 Short termSmooth transition expected with no immediate operational disruption as leadership changes are internal promotions.
📈 Long termEstablishes next-generation management leadership to drive execution across domestic and export agrochemical business lines.
⚠ Risk flags
- Shareholder approval pending at the AGM for director appointments and remuneration revisions
Key Highlights
Prashant Krishnamurthy re-designated as Managing Director effective November 01, 2026
Krishnamurthy Ganesan transitions from MD to Chairman and Executive Director effective November 01, 2026
Amarendra Mohapatra appointed as Chief Financial Officer (CFO) effective November 01, 2026
24th AGM scheduled for September 29, 2026 to approve director appointments and remuneration revisions
👀 What to Watch
Watch for shareholder approvals on board re-designations and executive remuneration at the upcoming 24th AGM on September 29, 2026.
Mahamaya Lifesciences Announces Key Leadership Transition and New CS Appointment
Mahamaya Lifesciences announced a major executive leadership restructuring following its board meeting on August 25, 2026. Managing Director Krishnamurthy Ganesan will step down to become Chairman and Executive Non-Independent Director effective November 1, 2026. Prashant Krishnamurthy will transition from CFO/Executive Director to Managing Director, while Amarendra Mohapatra takes over as the new Chief Financial Officer. Additionally, Kush Mishra has been appointed as Company Secretary and Compliance Officer effective August 25, 2026, and the 24th AGM is scheduled for September 29, 2026.
Confidence: HIGH
What changedTop executive succession plan executed: MD steps down to become Chairman, Executive Director becomes MD, and a new external professional is appointed CFO.
Why it mattersSeparates the CFO and MD roles while maintaining family promoter continuity and institutionalizing operational leadership.
AGM Date: September 29, 2026Leadership transition effective date: November 01, 2026CS appointment date: August 25, 2026FY26 Revenue (Context): Rs 329.0 Cr
📅 Short termNeutral operational update with no immediate financial impact; routine governance and compliance transition.
📈 Long termEnsures structured leadership succession within the promoter group while onboarding experienced finance leadership for the next growth phase.
⚠ Risk flags
- Subject to shareholder approval at the upcoming AGM
- Key executive remuneration revisions pending shareholder review
Key Highlights
Prashant Krishnamurthy re-designated as Managing Director and steps down as CFO effective November 01, 2026
Amarendra Mohapatra elevated to Chief Financial Officer (CFO) effective November 01, 2026
Krishnamurthy Ganesan transitions from MD to Chairman & Executive Director effective November 01, 2026
Kush Mishra appointed as Company Secretary and Compliance Officer effective August 25, 2026
24th Annual General Meeting (AGM) scheduled for September 29, 2026
👀 What to Watch
Track shareholder voting outcomes at the upcoming AGM on September 29, 2026, regarding the director appointments and executive remuneration revisions.
